Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $46.43.
Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research report on Friday, May 17th.
View Our Latest Stock Analysis on OTLK
Outlook Therapeutics Stock Performance
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($1.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.67). On average, equities analysts expect that Outlook Therapeutics will post -4.08 EPS for the current year.
Institutional Investors Weigh In On Outlook Therapeutics
A hedge fund recently bought a new stake in Outlook Therapeutics stock. LVW Advisors LLC bought a new stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 47,730 shares of the company’s stock, valued at approximately $352,000. LVW Advisors LLC owned about 0.20% of Outlook Therapeutics as of its most recent SEC filing. 11.20% of the stock is currently owned by hedge funds and other institutional investors.
About Outlook Therapeutics
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Further Reading
- Five stocks we like better than Outlook Therapeutics
- EV Stocks and How to Profit from Them
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Investing in large cap stocks: Diving into big caps
- Why Call Options Volume for These 2 Stocks Spiked Together
- What to Know About Investing in Penny Stocks
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.